Driving Productivity in Law Firms

Slides:



Advertisements
Similar presentations
Sovereign Credit Quality after the Crisis MARCH, 2010 Steve Hess, VP – Senior Credit Officer.
Advertisements

© 2013 Sri U-Thong Limited. All rights reserved. This presentation has been prepared by Sri U-Thong Limited and its holding company (collectively, “Sri.
Pension Fund Trustees Liability Ncedi Mbongwe. Introduction to Camargue Underwriting Managers Established in 2001 Underwriters: Mutual and Federal and.
IMPORTANT READ CAREFULLY BEFORE USING THIS PRODUCT LICENSE AGREEMENT AND LIMITED WARRANTY BY INSTALLING OR USING THE SOFTWARE, FILES OR OTHER ELECTRONIC.
PLEASE READ THIS CAREFULLY BEFORE YOU INSTALL OR USE ANY FILES YOUR RIGHT TO USE THIS SOFTWARE PRODUCT IS SUBJECT TO THE TERMS SET OUT IN THIS LICENCE.
Irish recovery? Pär Magnusson
Innovations in Structured Products October 25, 2010 An Innovator’s Dilemma?
NHS Pension Scheme Cornwall LMC – April 2015 Luke Bennett Alan Turner.
Education’s Value Proposition MARK ZANDI, CHIEF ECONOMIST FROM MOODY’S ECONOMY.COM.
STRICTLY CONFIDENTIAL Positioning for Growth Tasmanian Strata Industry Tim MacKenzie Associate Director Friday 9 th August.
An Equity Perspective Paul Malan Global Markets 21 January 2004.
Mike Zenker Barclays Capital Research (415) November 12, 2007
Social Investment Tax Relief (SITR) Tim Culverhouse - Partner 18 March 2014.
Client Update September 2013 Andrew Tasker – GFM Representative WA.
Permission to reprint or distribute any content from this presentation requires the prior written approval of Standard & Poor’s. Copyright © 2010 Standard.
DIRC Workshop on Software Quality and the Legal System 13 February 2004, Gray's Inn, London LEGAL ASPECTS OF SOFTWARE PROCUREMENT Jos Dumortier University.
Anticipated 2008 Generic Launches JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM © THOMSON REUTERS.
PRODUCTIVITY – THE PICTURE FOR THE UK & THE WEST MIDLANDS SUSTAINING COMPETITIVENESS CONFERENCE – THE BELFRY RHYS HERBERT SENIOR ECONOMIST 6 JULY 2012.
MESSAGING IN THE MEDIA TOP 10 DRUGS BASED ON CREDIBILITY INDEX IN THE LITERATURE JOHN KNAPP, DIRECTOR OF ANALYTICS MAY 2009 Your use of these materials.
Client:x Product:x Report: Outdoor Site Inspection Report.
Therapeutic area breakdown of lead projects in development for first launch in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM ©
Permission to reprint or distribute any content from this presentation requires the prior written approval of Standard & Poor’s. Copyright © 2014 by Standard.
Paragraph IV Patent Challenges – As of July 1, 2008 JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM.
Proposal Insert Subtitle Here Strictly Private and Confidential Draft December 8, 2014 Risk Management guidance box Guidance when using Smart Transaction.
Proportion of biotech-derived active substances in development for first launch 31st December APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
International Telecommunication Union New Delhi, India, December 2011 ITU Workshop on Standards and Intellectual Property Rights (IPR) Issues Philip.
W Geneva December, 2007 World Meteorological Organization Basics of Weather Risk Management.
Results March Disclaimer The information in this presentation does not constitute or form any part of, and should not be construed as,
Place Client Logo Here Oil Market Outlook Paul Horsnell Head of Commodities Research, Barclays Capital Intertanko Singapore Tanker Event 30 March 2006.
Proportion of total R&D expenditure by therapeutic area in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Manage and Disposition Inventory Returns.
Global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output MARCH 2008 SOURCE: CMR INTERNATIONAL.
2005/2006 Expenditure on biotech derived entities had remained constant APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
Number of pharmaceutical patent applications and granted patents for 5 major patent issuing authorities JUNE 2008 SOURCE: DERWENT WORLD PATENTS.
Evolution not revolution Trends in Compliance functions Kirsty Searles.
© 2003 The McGraw-Hill Companies, Inc., All Rights Reserved 1 Chapter 2 Partnership Organization and Operation.
©The McGraw-Hill Companies, Inc. 2006McGraw-Hill/Irwin Chapter 2 Partnership Organization and Operation.
Regulatory approval times between submission and marketing authorization approval APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
Availability of High-Quality API for India, China and Rest of World MARCH 2008 David Harding, API Intelligence, Thomson Reuters Source: NEWPORT HORIZON.
Innovation driven by regulation The changing face of cash investment 23 February 2016 Leigh Mahoney and Matthew Byrne ANZ Bank.
Allocation of R&D expenditure in 2005 between chemical entity and biological or biotech active substances APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Permission to reprint or distribute any content from this presentation requires the prior written approval of Standard & Poor’s. Copyright © 2011 Standard.
Q Regional Scenario Analysis PwCAutomotiveInstitute RegionX Scenarios 2008 – 2015 (Millions) In our volatile marketplace, blind reliance upon a single-point.
The secure site rendering issue (all navigation crushed together as a list at the top of the page) is a compatibility issue with Internet Explorer only.
Copyright © 2012, Oracle and/or its affiliates. All rights reserved. Oracle Proprietary and Confidential. 1.
01 Autofacts 2011 Q1 Autofacts ® SWOT analysis Alliance Group ? 200? Q?
Camargue Commercial Crime
Connectivity to bank and sample account structure
RaboDirect Financial Health Barometer 2016
Achieving innovation to meet new market challenges: Global Commodity Financing GTR MENA Oscar Wehtje, Head of Product Development February 2017.
Michael H. Lieberman Partner, Norton Rose Fulbright Canada LLP
BIOLOGY / CHEMISTRY CITATIONS GROWTH
Rising Momentum Trumps Policy Uncertainty
Messaging in the Media TOP 10 AUDIENCES BY THERAPY AREA
Self-Registration walk-through
2006 Revenue continued to depend on a relatively small number of products APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
, R&D expenditure showed 6% growth annually
A Practical Approach to the New Accounts Rules
Pamplona Credit Opportunities Fund
2002–2006 Mid and Other sized companies continued to launch the majority of NMEs APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON.
Financial Compliance Update
Proportion of total R&D expenditure on alliances or joint ventures by stage of R&D in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
% of the projects in development in the leading therapeutic areas were considered to have a novel mode of action APRIL 2007 SOURCE: CMR INTERNATIONAL.
Environmental Upgrade Finance
Pipeline size of Major companies had grown at a steadier rate than that of smaller companies APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Development time for new molecular entities first launched onto the world market between MARCH 2008 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS.
Cycle times decreased in larger but not smaller, companies
Proportion of total R&D expenditure by function in 2005
© 2013 Sri U-Thong Limited. All rights reserved
AUTHOR JOBTITLE PRESENTATIONDATE
Presentation transcript:

Driving Productivity in Law Firms Andrew Allen November 2017

Application to “a law firm” Impact of model variables Overview Profit making model Explanation of model Application to “a law firm” Impact of model variables Improving productivity Practical MI pkf-francisclark.co.uk

Profit making model GEARING HOURS RATE RECOVERY MARGIN X X X X

Profit making model GEARING HOURS RATE RECOVERY MARGIN X X X X G5 Team size per EP Productive time Average rate? Billing skills Overhead management GEARING HOURS RATE RECOVERY MARGIN X X X X G5 G1,150 £130 80% 23%

PEP £137,000 Profit making model GEARING HOURS RATE RECOVERY MARGIN X Team size per EP Productive time Average rate Billing skills Overhead management PEP £137,000 GEARING HOURS RATE RECOVERY MARGIN X X X X G5 1,150 £300 80% 23%

Profit making model –Future ? Team size per EP Productive time Average rate Billing skills Overhead management GEARING HOURS RATE RECOVERY MARGIN X X X X G5 1,200 £130 90% 23%

PEP £161,000 Profit making model GEARING HOURS RATE RECOVERY MARGIN X Team size per EP Productive time Average rate Billing skills Overhead management PEP £161,000 GEARING HOURS RATE RECOVERY MARGIN X X X X G5 1,200 £300 90% 23%

Profit making model Chargeable hours? (and raised recovery to 90%) 52 weeks less 6 weeks holiday x 5 working days x 5.0 hours per day = 1,150 PEP = £155,000 (PEP increase = 13%) 52 weeks less 6 weeks holiday x 5 working days x 5.5 hours per day = 1,265 PEP = £170,000 (PEP increase = 24%) 52 weeks less 6 weeks holiday x 5 working days x 6.0 hours per day = 1,380 PEP = £186,000 (PEP increase = 36%)

Profit making model Average rate and hours increased? (80% recovery retained) Increase average hourly rate from £130 to £150 creates PEP of £159,000; an increase of £22,000 on the base model (16%) Increasing average hourly rate from £130 to £150 AND increasing chargeable hours average to 5.5 hours per day creates PEP of £175,000; an increase of £38,000 on the base model (28%) Increasing average hourly rate from £130 to £150 AND increasing chargeable hours average from 5.0 hours per day to 6.0 hours per day creates PEP of £190,000; an increase of £53,000 on the base model (39%)

Profit making model – Practical actions? Based on a typical law firm…. Actual Fees per fee earner in 2017 = £120k 20 Employed fee earners plus 5 equity partner fee earners – so 5 fee earners per partner PEP achieved £130k Increase fees per fee earner £5k to £125k So; every fee earner on average increases their recovered fees by £5k with no other additional costs i.e. from productivity improvements Extra 125k of fee, no additional costs, divided by 5 partners Increase in PEP = £25k (19%)

Profit making model – Practical actions? Achieving extra £5k on average? (Equivalent to £20 per working day per fee earner) Fee negotiation / scoping Time recording / capturing improvements Controls over extra service delivery 2nd partner / fee earner reviews of write offs Setting chargeable hours and recovery rate targets …..not necessarily by doing more work! (What would a £10k improvement take to achieve PEP growth of £50k? )

Influencing the model – Practical actions? Chargeable hours Partner driven behaviour Budgets & MI; reviewed Time management training Time recording processes Software advancements Reward structure Rate and recovery Partner driven behaviour Budgets & MI; reviewed Fee negotiation training Second review of write offs Second review of budgets Client communication Work allocation (margin) Reward structure

Profit making model – MI provision Partner Driven Regular MI (all month and ytd vs Budget) Chargeable hours Fees Recovery Debtors WIP Ensure the focus is a “recovery culture” not a hours culture

Profit making model - Summary Your role as partners….. Get good people Record time (keep them busy) Think about pricing and billing the time Get better at bringing in new business

Regulatory update and outlook SRA AR Phase 3 Provision of banking services VAT on disbursements pkf-francisclark.co.uk

Contact Andrew Allen Andrew.Allen@pkf-francisclark.co.uk

Disclaimer & copyright (c) copyright PKF Francis Clark, 2017 You shall not copy, make available, retransmit, reproduce, sell, disseminate, separate, licence, distribute, store electronically, publish, broadcast or otherwise circulate either within your business or for public or commercial purposes any of (or any part of) these materials and / or any services provided by PKF Francis Clark in any format whatsoever unless you have obtained prior written consent from PKF Francis Clark to do so and entered into a licence. To the maximum extent permitted by applicable law PKF Francis Clark excludes all representations, warranties and conditions (including, without limitation, the conditions implied by law) in respect of these materials and /or any services provided by PKF Francis Clark. These materials and /or any services provided by PKF Francis Clark are designed solely for the benefit of delegates of PKF Francis Clark. The content of these materials and / or any services provided by PKF Francis Clark does not constitute advice and whilst PKF Francis Clark endeavours to ensure that the materials and / or any services provided by PKF Francis Clark are correct, we do not warrant the completeness or accuracy of the materials and /or any services provided by PKF Francis Clark; nor do we commit to ensuring that these materials and / or any services provided by PKF Francis Clark are up-to-date or error or omission-free. Where indicated, these materials are subject to Crown copyright protection. Re-use of any such Crown copyright-protected material is subject to current law and related regulations on the re-use of Crown copyright extracts in England and Wales. These materials and / or any services provided by PKF Francis Clark are subject to our terms and conditions of business as amended from time to time, a copy of which is available on request. Our liability is limited and to the maximum extent permitted under applicable law PKF Francis Clark will not be liable for any direct, indirect or consequential loss or damage arising in connection with these materials and / or any services provided by PKF Francis Clark, whether arising in tort, contract, or otherwise, including, without limitation, any loss of profit, contracts, business, goodwill, data, income or revenue. Please note however, that our liability for fraud, for death or personal injury caused by our negligence, or for any other liability is not excluded or limited. PKF Francis Clark is a trading name of Francis Clark LLP. Francis Clark LLP is a limited liability partnership, registered in England and Wales with registered number OC349116. The registered office is Sigma House, Oak View Close, Edginswell Park, Torquay TQ2 7FF where a list of members is available for inspection and at www.pkf-francisclark.co.uk. The term ‘Partner’ is used to refer to a member of Francis Clark LLP or to an employee. Registered to carry on audit work in the UK and Ireland, regulated for a range of investment business activities and licensed to carry out reserved legal activity of non-contentious probate in England and Wales by the Institute of Chartered Accountants in England and Wales. Partners acting as insolvency practitioners are licensed in the UK by the Institute of Chartered Accountants in England and Wales. A partner appointed as Administrator or Administrative Receiver acts only as agent of the insolvent entity and without personal liability. Francis Clark LLP is a member firm of the PKF International Limited network of legally independent firms and does not accept responsibility or liability for the actions or inactions on the part of any other individual member firm or firms. pkf-francisclark.co.uk